Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropeginterferon alfa-2b + ruxolitinib
- Development stage
- Unknown
- Lead developer
- PharmaEssentia
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Ropeginterferon alfa-2b + ruxolitinib is a combination therapy being investigated for the treatment of myelofibrosis, particularly in patients who have demonstrated a suboptimal response to ruxolitinib monotherapy. Ropeginterferon alfa-2b (Besremi) is a next-generation, long-acting monopegylated interferon-alpha-2b that acts as an agonist for the interferon-alpha/beta receptor (IFNAR), inducing antiproliferative and immunomodulatory effects on hematopoietic stem cells. Ruxolitinib (Jakafi/Jakavi) is a small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/JAK2), which are often constitutively active in myeloproliferative neoplasms. The University of Hong Kong is sponsoring a Phase 2 clinical trial to evaluate the safety and efficacy of adding ropeginterferon alfa-2b to a stable regimen of ruxolitinib, aiming to achieve deeper molecular responses and improved clinical outcomes by simultaneously targeting the JAK-STAT pathway and the interferon signaling pathway.
- Brand names
- BesremiJakafiJakavi
- Other names
- Ropeginterferon alfa-2b and ruxolitinibRopeginterferon alfa-2b in combination with ruxolitinib
02
Targets
JAK1 (Janus kinase 1)IFNAR (Immune system modulation via type I interferon receptor)JAK2 (Janus kinase 2)
Beyond the preview
Go deeper on ropeginterferon alfa-2b + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropeginterferon alfa-2b + ruxolitinib.